Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison.
Philip D HomeVanita R ArodaLawrence BlondePatricia GuyotAlka ShaunikMir Sohail FazeliHardik GoswamiSanjay KalraMir-Masoud PourrahmatPublished in: Diabetes, obesity & metabolism (2020)
Results of this indirect treatment comparison using two studies suggest iGlarLixi and IDegLira appear to offer similar benefits for HbA1c target achievement. However, the findings suggest differences in other glycaemia results and hypoglycaemia, which may reflect differences in study design and titration approaches.